Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still varies across practice settings nationwide.
Choosing between FOLFOX and FOLFIRI, and deciding when to shift to maintenance therapy, requires balancing prior treatment exposure, patient lifestyle, and the limited pool of active agents in colorectal cancer.
KEYNOTE-177 and CheckMate-8HW established immunotherapy as the frontline standard for MSI-high and deficient mismatch repair colorectal cancer, though managing the smaller subset of patients who progress remains genuinely complex.
Defining treatment failure depends on disease burden and biology, while circulating tumor DNA offers real but still limited practical value in guiding second-line therapy selection for metastatic colorectal cancer.
Early planning for third-line therapy, guided by subtle clinical and biochemical signals, now shapes how oncologists distinguish a true treatment rechallenge from a simple reintroduction of prior therapy.
Unresolved questions about immunotherapy duration, right-sided tumor biology, and earlier use of targeted agents illustrate how much remains unsettled in first- and second-line colorectal cancer management.
The SUNLIGHT trial redefined third-line expectations by pairing trifluridine and tipiracil with bevacizumab, while emerging every-other-week dosing data promise better tolerability without sacrificing efficacy.
Positioning fruquintinib and regorafenib against each other, and against trifluridine and tipiracil plus bevacizumab, increasingly comes down to individual tolerability, disease burden, and appropriate dose escalation strategy.
